Opportunities and Challenges for Molecular Chaperone Modulation to Treat Protein-Conformational Brain Diseases

Neurotherapeutics

Volumn 10, Issue 3, 2013, Pages 416-428

  van der Putten, Herman ^a   Lotz, Gregor P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aggregation; Molecular chaperones; Neurodegenerative diseases; Protein clearance; Protein folding

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CHAPERONE; CHAPERONIN 60; GELDANAMYCIN; HEAT SHOCK PROTEIN 22; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; HISTONE DEACETYLASE INHIBITOR; RADICICOL;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LEWY BODY; NEUROMODULATION; NEUROPHARMACOLOGY; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; POLYQ DISEASE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN QUALITY; REVIEW;

ANIMALS; BRAIN; HUMANS; MOLECULAR CHAPERONES; PROTEOSTASIS DEFICIENCIES;

EID: 84879983520     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-013-0186-5     Document Type: Review

References (165)

1. Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005;6: 11-22.
2. Young JC, Agashe VR, Siegers K, Hartl, FU. Pathways of chaperone mediated protein folding in the cytosol. Nat Rev Mol Cell Biol 2004;5: 781-791.
3. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature 2011;475: 324-332.
4. Vos MJ, Hageman J, Carra S, Kampinga HH. Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. Biochemistry 2008;47: 7001-7011.
5. Feldman DE, Frydman J. Protein folding in vivo: the importance of molecular chaperones. Curr Opin Struct Biol 2000;10: 26-33.
6. Ellis RJ, Hartl FU. Principles of protein folding in the cellular environment. Curr Opin Struct Biol 1999;9: 102-110.
7. Shashidharamurthy R, Koteiche HA, Dong J, McHaourab, HS. Mechanism of chaperone function in small heat shock proteins: Dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme. J Biol Chem 2005;280: 5281-5289.
8. Ito H, Kamei K, Iwamoto I, Inaguma Y, Nohara D, Kato, K. Phosphorylation-induced change of the oligomerization state of RB-crystallin. J Biol Chem 2001;276: 5346-5352.
9. van Montfort RL, Basha E, Friedrich KL, Slingsby C, Vierling, E. Crystal structure and assembly of a eukaryotic small heat shock protein. Nat Struct Biol 2001;8: 1025-1030.
10. Bryantsev AL, Kurchashova SY, Golyshev SA, et al. Regulation of stress-induced intracellular sorting and chaperone function of Hsp27 (HspB1) in mammalian cells. Biochem J 2007;407: 407-417.
11. Carra S, Seguin SJ, Lambert H, Landry J. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 2008;283: 1437-1444.
12. Carra S. The stress-inducible HspB8-Bag3 complex induces the eIF2alpha kinase pathway: implications for protein quality control and viral factory degradation? Autophagy 2009;5: 428-429.
13. Vos MJ, Zijlstra MP, Kanon B, et al. HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones. Hum Mol Genet 2010;19: 4677-4693.
14. Vos MJ, Zijlstra MP, Carra S, Sibon OC, Kampinga HH. Small heat shock proteins, protein degradation and protein aggregation diseases. Autophagy 2011;7: 101-103.
15. Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010;13: 567-576.
16. Carra S, Crippa V, Rusmini P, et al. Alteration of protein folding and degradation in motor neuron diseases: Implications and protective functions of small heat shock proteins. Prog Neurobiol 2012;97: 83-100.
17. Boncoraglio A, Minoia M, Carra S. The family of mammalian small heat shock proteins (HSPBs): implications in protein deposit diseases and motor neuropathies. Int J Biochem Cell Biol 2012;44: 1657-1669.
18. Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 2010;11: 579-592.
19. Hageman J, van Waarde MA, Zylicz A, Walerych D, Kampinga HH. The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities. Biochem J 2011;435: 127-142.
20. Sterrenberg JN, Blatch GL, Edkins AL. Human DNAJ in cancer and stem cells. Cancer Lett 2011;312: 129-142.
21. Kalia SK, Kalia LV, McLean PJ. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics. CNS Neurol Disord Drug Targets 2010;9: 741-753.
22. Mitra A, Shevde LA, Samant RS. Multi-faceted role of HSP40 in cancer. Clin Exp Metastasis 2009;26: 559-567.
23. Harms MB, Sommerville RB, Allred P, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol 2012;71: 407-416.
24. Westhoff B, Chapple JP, van der Spuy J, Hohfeld J, Cheetham ME. HSJ1 is a neuronal shuttling factor for the sorting of chaperone clients to the proteasome. Curr Biol 2005;15: 1058-1064.
25. Labbadia J, Novoselov SS, Bett JS, et al. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 2012;135: 1180-1196.
26. Howarth JL, Kelly S, Keasey MP, et al. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther 2007;15: 1100-1105.
27. Blumen SC, Astord S, Robin V, et al. A rare recessive distal hereditary motor neuropathy with HSJ1 chaperone mutation. Ann Neurol 2012;71: 509-519.
28. Hageman J, Rujano MA, van Waarde MA, et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 2010; 37: 355-369.
29. Durrenberger PF, Filiou MD, Moran LB, et al. DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytes. J Neurosci Res 2009;87: 238-245.
30. Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 2012;44: 450-455.
31. Parfitt DA, Michael GJ, Vermeulen EG, et al. The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1. Hum Mol Genet 2009;18: 1556-1565.
32. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 2005;62: 670-684.
33. Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 2010;53: 4585-4602.
34. Dragovic Z, Broadley SA, Shomura Y, Bracher A, Hartl FU. Molecular chaperones of the Hsp110 family act as nucleotide exchange factors of Hsp70s. EMBO J 2006;25: 2519-2528.
35. Schaffar G, Breuer P, Boteva R, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004;15: 95-105.
36. Lotz GP, Legleiter J, Aron R, et al. Hsp70 and Hsp40 functionally interact with soluble mutant huntingtin oligomers in a classic ATP-dependent reaction cycle J Biol Chem 2010;285: 38183-38193.
37. Auluck PK, Chan HYE, Trojanowski JQ, Lee VMY, Bonini NM. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295: 865-868.
38. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-18477.
39. Richter K, Muschler P, Hainzl O, Reinstein J, Buchner J. Sti1 is a non-competitive inhibitor of the Hsp90 ATPase. Binding prevents the N-terminal dimerization reaction during the atpase cycle. J Biol Chem 2003;278: 10328-10333.
40. Caplan AJ, Mandal AK, Theodoraki MA. Molecular chaperones and protein kinase quality control. Trends Cell Biol 2007;17: 87-92.
41. Lotz GP, Lin H, Harst A, Obermann WM. Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem 2003;278: 17228-17235.
42. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396: 336-342.
43. Baldo B, Weiss A, Parker CN, Bibel M, Paganetti P, Kaupmann K. A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J Biol Chem 2012;287: 1406-1414.
44. Munoz IG, Yébenes H, Zhou M, et al. Crystal structure of the open conformation of the mammalian chaperonin CCT in complex with tubulin. Nat Struct Mol Biol 2011;18: 14-19.
45. Douglas NR, Reissmann S, Zhang J, et al. Dual action of ATP hydrolysis couples lid closure to substrate release into the Group II chaperonin chamber. Cell 2011;144: 240-252.
46. Kitamura A, Kubota H, Pack CG, et al. Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol 2006;8: 1163-1170.
47. Behrends C, Langer CA, Boteva R, et al. Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell 2006;23: 887-897.
48. Tam S, Geller R, Spiess C, Frydman J. The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol 2006;8: 1155-1162.
49. Bross P, Naundrup S, Hansen J, et al. The Hsp60-(p. V98I) mutation associated with hereditary spastic paraplegia SPG13 compromises chaperonin function both in vitro and in vivo. J Biol Chem 2008;283: 15694-15700.
50. Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci U S A 2010;107: 1488-1489.
51. Koga H, Kaushik S, Cuervo AM. Protein homeostasis and aging: The importance of exquisite quality control. Ageing Res Rev 2011;10: 205-215.
52. Calderwood SK, Murshid A, Prince T. The shock of aging: molecular chaperones and the heat shock response in longevity and aging-a mini-review. Gerontology 2009: 55: 550-558.
53. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012;148: 1204-1222.
54. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010;11: 155-159.
55. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012;287: 19440-19451.
56. Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009;187: 761-772.
57. Yoo BC, Seidl R, Cairns N, Lubec G. Heat-shock protein 70 levels in brain of patients with Down syndrome and Alzheimer's disease. J Neural Transmission 1999;57(Suppl.): 315-322.
58. Renkawek K, Bosman GJ, de Jong WW. Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathol 1994;87: 511-519.
59. Evans CG, Wisén S, Gestwicki JE. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J Biol Chem 2006;281: 33182-33191.
60. Magrané J, Smith RC, Walsh K, Querfurth HW. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J Neurosci 2004;24: 1700-1706.
61. Fonte V, Kipp DR, Yerg J 3rd, et al. Suppression of in vivo beta-amyloid peptide toxicity by overexpression of the HSP-16. 2 small chaperone protein. J Biol Chem 2008;283: 784-791.
62. Wilhelmus MM, Boelens WC, Otte-Höller I, Kamps B, de Waal RM, Verbeek MM. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity Brain Res 2006;17: 67-78.
63. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. Opposing activities protect against age-onset proteotoxicity. Science 2006;313: 1604-1610.
64. Petrucelli L, Dickson D, Kehoe K, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 2004;13: 703-714.
65. Shimura H, Miura-Shimura Y, Kosik KS. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival. J Biol Chem 2004;279: 17957-17962.
66. Thompson AD, Scaglione KM, Prensner J, et al. Analysis of the tau-associated proteome reveals that exchange of hsp70 for hsp90 is involved in tau degradation. ACS Chem Biol 2012;7: 1677-1686.
67. Dou F, Netzer WJ, Tanemura K, et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 2003;100: 721-726.
68. Dickey CA, Kamal A, Lundgren K, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117: 648-658.
69. Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer's disease. Prog Neurobiol 2011;93: 99-110.
70. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388: 839-840.
71. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003;302: 841.
72. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364: 1167-1169.
73. Cronin KD, Ge D, Manninger P, et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum Mol Genet 2009;18: 3274-3285.
74. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276: 2045-2047.
75. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18: 106-108.
76. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55: 164-173.
77. Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models Science 2006;313: 324-328.
78. Nemani VM, Lu W, Berge V, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010;65: 66-79.
79. Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs Mol Biol Cell 2010;21: 1850-1863.
80. Nakamura K, Nemani VM, Azarbal F, et al. Direct membrane association drives mitochondrial fission by the Parkinson's disease-associated protein α-synuclein. J Biol Chem 2011;286: 20710-20726.
81. Bartels T, Choi JG, Selkoe DJ. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011;477: 107-110.
82. McLean PJ, Kawamata H, Shariff S, et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 2002;83: 846-854.
83. Uryu K, Richter-Landsberg C, Welch W, et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alphasynucleinopathies Am J Pathol 2006;168: 947-961.
84. Leverenz JB, Umar I, Wang Q, et al. Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol 2007;17: 139-145.
85. Auluck PK, Meulener MC, Bonini NM. Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. J Biol Chem 2005;280: 2873-2878.
86. Dedmon MM, Christodoulou J, Wilson MR, Dobson CM. Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem 2005;280: 14733-14740.
87. Lindersson E, Beedholm R, Hojrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004;279: 12924-12934.
88. Pemberton S, Madiona K, Pieri L, Kabani M, Bousset L, Melki R. Hsc70 Protein interaction with soluble and fibrillar {alpha}-Synuclein. J Biol Chem 2011;286: 34690-34699.
89. Roodveldt C, Bertoncini CW, Andersson A, et al. Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip. EMBO J 2009;28: 3758-3770.
90. Luk KC, Mills IP, Trojanowski JQ, Lee VM. Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. Biochemistry 2008;47: 12614-12625.
91. Huang C, Cheng H, Hao S, et al. Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J Mol Biol 2006;364: 323-336.
92. Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alphasynuclein oligomeric species by fluorescence lifetime imaging. FASEB J 2006;20: 2050-2057.
93. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004;279: 25497-25502.
94. Shimshek DR, Mueller M, Wiessner C, Schweizer T, van der Putten PH. The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy. PLoS One 2010;5: e10014.
95. Tsai YC, Fishman PS, Thakor NV, Oyler GA. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 2003;278: 22044-22055.
96. Falsone SF, Kungl AJ, Rek A, Cappai R, Zangger K. The molecular chaperone Hsp90 modulates intermediate steps of amyloid assembly of the Parkinson-related protein alpha-synuclein. J Biol Chem 2009;284: 31190-31199.
97. Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of alpha-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2- associated athanogene 5 (BAG5). PLoS One 2011;6: e14695.
98. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 2005;280: 23727-23734.
99. Tetzlaff JE, Putcha P, Outeiro TF, et al. CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem 2008;283: 17962-17968.
100. Ding X, Goldberg MS. Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PloS One 2009;4: e5949.
101. Ko HS, Bailey R, Smith WW, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A 2009;106: 2897-2902.
102. Zourlidou A, Payne Smith MD, Latchman DS. HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 2004;88: 1439-1448.
103. Iwaki T, Wisniewski T, Iwaki A, et al. Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions. Am J Pathol 1992;140: 345-356.
104. Braak H, Del Tredici K, Sandmann-Kiel D, Rub U, Schultz C. Nerve cells expressing heat-shock proteins in Parkinson's disease. Acta Neuropathol 2001;102: 449-454.
105. Rose JM, Novoselov SS, Robinson PA, Cheetham ME. Molecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutant. Hum Mol Genet 2011;20: 16-27.
106. Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. Polyglutamine protein aggregates are dynamic. Nat Cell Biol 2002;4: 826-831.
107. Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998: 93;939-949.
108. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999;23: 425-428.
109. Hansson O, Nylandsted J, Castilho RF, Leist M, Jäättelä M, Brundin P. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Res 2003;970: 47-57.
110. Rujano MA, Kampinga HH, Salomons FA. Modulation of polyglutamine inclusion formation by the Hsp70 chaperone machine. Exp Cell Res 2007;313: 3568-3578.
111. Miller VM, Nelson RF, Gouvion CM, et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 2005;25: 9152-9161.
112. Jana NR, Dikshit P, Goswami A, et al. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 2005;280: 11635-11640.
113. Al-Ramahi I, Lam YC, Chen HK, et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem 2006;281: 26714-26724.
114. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer Nat Struct Mol Biol 2004;11: 1215-1222.
115. Helmlinger D, Bonnet J, Mandel JL, Trottier Y, Devys D. Hsp70 and Hsp40 chaperones do not modulate retinal phenotype in SCA7 mice. J Biol Chem 2004;279: 55969-55977.
116. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3: 711-715.
117. Selkoe DJ Preventing Alzheimer's disease. Science 2012;337: 1488-1492.
118. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012;18: 64-76.
119. The HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012;11: 264-278.
120. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of Parkinson's disease. Proc Natl Acad Sci U S A 2008;105: 5856-5861.
121. Tomaskovic-Crook E, Crook JM. Human embryonic stem cell therapies for neurodegenerative diseases. CNS Neurol Disord Drug Targets 2011;10: 440-448.
122. Wray S, Self M, NINDS Parkinson's Disease iPSC Consortium, NINDS Huntington's Disease iPSC Consortium, et al. Creation of an Open-access, mutation-defined fibroblast resource for neurological disease research. PLoS One 2012;7(8): e43099.
123. Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011;480: 543-546.
124. Bilican B, Serio A, Barmada SJ, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A 2012;109: 5803-5808.
125. Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 2012;4: 124-129.
126. Camnasio S, Delli Carri A, Lombardo A, et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012;46: 41-51.
127. Liu GH, Qu J, Suzuki K, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012;491: 603-607.
128. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012;4: 380-395.
129. Devine MJ, Ryten M, Vodicka P, et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 2011;2: 440.
130. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146: 37-52.
131. Soga S, Akinaga S, Shiotsu Y. Hsp90 Inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013;19: 366-376.
132. Assimon VA, Gillies AT, Rauch JN, Gestwicki JE. Hsp70 protein complexes as drug targets. Curr Pharm Des 2013;19: 404-417.
133. Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11: 1088-1095.
134. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 2005;280: 33097-33100.
135. Labbadia J, Cunliffe H, Weiss A, et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 2011;121: 3306-3319.
136. Chafekar SM, Duennwald ML. Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One 2012;7: e37929.
137. Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008;15: 2702-2717.
138. Yi F, Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol 2008;3: 645-654.
139. Ansar S, Burlison JA, Hadden MK, et al. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett 2007;17: 1984-1990.
140. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J Biol Chem 2005;280: 26729-26734.
141. Koulov AV, Lapointe P, Lu B, et al. Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis. Mol Biol Cell 2010;21: 871-884.
142. Miyata Y, Koren J, Kiray J, Dickey CA, Gestwicki JE. Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem 2011;3: 1523-1537.
143. Sahara N, Maeda S, Yoshiike Y, et al. Molecular chaperone mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain. J Neurosci Res 2007;85: 3098-3108.
144. Abisambra JF, Jinwal UK, Suntharalingam A, et al. DnaJA1 Antagonizes Constitutive Hsp70-Mediated Stabilization of Tau. J Mol Biol 2012;421: 653-661.
145. Fewell SW, Smith CM, Lyon MA, et al. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J Biol Chem 2004;279: 51131-51140.
146. Wisen S, Bertelsen EB, Thompson AD, et al. Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem Biol 2010;5: 611-622.
147. Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol 2011;2011: 232037.
148. Walter GM, Smith MC, Wisen S, et al. Ordered assembly of heat shock proteins, Hsp26, Hsp70, Hsp90, and Hsp104, on expanded polyglutamine fragments revealed by chemical probes. J Biol Chem 2011;286: 40486-40493.
149. Jinwal UK, Miyata Y, Koren J, 3rd, et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J Neurosci 2009;29: 12079-12088.
150. Rampelt H, Kirstein-Miles J, Nillegoda NB, et al. Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 2012;31: 4221-4235.
151. Kabbage M, Dickman MB. The BAG proteins: a ubiquitous family of chaperone regulators. Cell Mol Life Sci 2008;65: 1390-1402.
152. Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. The cochaperone BAG2 sweeps paired helical filamentinsoluble tau from the microtubule. J Neurosci 2009;29: 2151-2161.
153. Elliott E, Tsvetkov P, Ginzburg I. BAG-1 associates with Hsc70Tau complex and regulates the proteasomal degradation of Tau protein. J Biol Chem 2007;282: 37276-37284.
154. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001;3: 93-96.
155. Qian SB, McDonough H, Boellmann F, Cyr DM, Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 2006;440: 551-555.
156. Hutchison KA, Dittmar KD, Czar MJ, Pratt WB. Proof that hsp70 is required for assembly of the glucocorticoid receptor into a heterocomplex with hsp90. J Biol Chem 1994;269: 5043-5049.
157. Danzer KM, Kranich LR, Ruf WP, et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener 2012;7: 42.
158. Danzer KM, Ruf WP, Putcha P, et al. Heatshock protein 70 modulates toxic extracellular alphα-synuclein oligomers and rescues transsynaptic toxicity. FASEB J 2011;25: 326-336.
159. Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase J Clin Invest 2006;116: 1410-1424.
160. Marinova Z, Ren M, Wendland JR, et al. Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 2009;111: 976-987.
161. Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009;323: 1063-1066.
162. Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. HDAC inhibitors and chaperone function. Adv Cancer Res 2012;116: 239-262.
163. Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS One 2012;7(2): e31080.
164. Tam S, Spiess C, Auyeung W, et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat Struct Mol Biol 2009;16: 1279-1285.
165. Yam AY, Xia Y, Lin HT, Burlingame A, Gerstein M, Frydman J. Defining the TRiC/CCT interactome links chaperonin function to stabilization of newly made proteins with complex topologies. Nat Struct Mol Biol 2008; 15: 1255-1262.